Skip to main content

Replimune Group, Inc.

corporate_fare Company Profile

Replimune Group, Inc.

REPL·NASDAQ·Life Sciences·CIK 0001737953

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed to activate the immune system against cancer. Oncolytic immunotherapy uses certain viruses that can selectively replicate in and directly kill tumors, and also trigger a strong, patient-specific, anti-tumor immune response. Replimune's product candidates integrate multiple mechanisms into an "off-the-shelf" approach to maximize the immune response against a patient's cancer. The company's proprietary RPx platform uses a novel, engineered strain of herpes simplex virus 1 (HSV-1) backbone, with added payloads designed to maximize immunogenic cell death and induce a systemic anti-tumor immune response. The RPx platform aims for dual local and systemic activity: direct virus-mediated killing of the tumor, which releases tumor-derived antigens, and altering the tumor microenvironment to initiate a strong and lasting systemic response. Replimune expects its product candidates to work synergistically with most established and experimental cancer treatments and, due to their safety profile, the RPx platform is expected to be versatile enough for development alone or in combination with other treatments. Replimune currently has two RPx product candidates in its development pipeline: RP1 (vusolimogene oderparepvec), its lead product candidate, and RP2 (sturlimgene erparepvec). The company has been conducting several clinical trials for RP1, both as a single therapy and combined with anti-PD-1 therapy, with the aim of establishing a major skin cancer treatment franchise. While the fiscal year ends March 31st, program updates are reported on a calendar year basis.

Replimune Group, Inc. (NASDAQ:REPL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for REPL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for REPL spans 10-Q, 8-K, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • Replimune 10-Q: $307.8M Cash, Quarterly Loss Narrows to $57.1M, $15M Hercules Draw
  • Replimune Posts Q2 FY2027 Results: First TUDRIQEV Launch Metrics, $307.8M Cash
  • Replimune Posts $57.1M Quarterly Loss as TUDRIQEV Launch Reaches 15+ Institutions
  • Replimune 10-Q: Going Concern Lifted After $141M Raise and FDA Approval
  • Replimune Posts Q1 Loss, Appoints Chief Commercial Officer Ahead of TUDRIQEV Launch

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$313.94M
Diluted EPS
-$3.38
Op. Cash Flow
-$280.34M
Free Cash Flow
-$284.57M
Operating Income
-$319.92M
Cash & Equivalents
$209.02M
Total Debt
$83.31M
Debt / Equity
0.50×
Shares Outstanding
82.72M sh
Source: 10-K · filed 2026-06-29 · accession 0001628280-26-045886

Short Interest & Short Volume

8.31 days to cover

FINRA reported short interest of 24,609,876 shares in REPL as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 49.2% of REPL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,609,876 shares as of October 30, 2026
Change vs prior period▲ 6.2%
Days to cover8.31 at avg daily volume of 2,959,938
Daily short volume (FINRA facilities)49.2% of 644,522 shares on November 20, 2026
5-day average short volume50.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for REPL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.

1 recent capital raise1 shelf registration

$150M Offering Priced at Premium · Net Proceeds of ~$140.5M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$19.09 +0.10% today
52-week range · as of 2026-10-28 $1.5 – $19.09
Market cap
$1.81B
Volume
2M (0.7× avg)
3-mo avg 2.9M
Live data · 2026-11-21 23:19 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed REPL - Latest Insights

REPL
Oct 28, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.99
Real-time Price: $19.09 info
Change: +$6.10 (+47%) info
Market Cap: $1.808B info
REPL
Oct 28, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.99
Real-time Price: $19.09 info
Change: +$6.10 (+47%) info
Market Cap: $1.808B info
REPL
Oct 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.99
Real-time Price: $19.09 info
Change: +$6.10 (+47%) info
Market Cap: $1.808B info
REPL
Aug 14, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.80
Real-time Price: $19.09 info
Change: +$4.29 (+29%) info
Market Cap: $1.808B info
REPL
Aug 14, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.98
Real-time Price: $19.09 info
Change: +$4.11 (+27%) info
Market Cap: $1.808B info
REPL
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.98
Real-time Price: $19.09 info
Change: +$4.11 (+27%) info
Market Cap: $1.808B info
REPL
Aug 11, 2026, 5:50 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $13.70
Real-time Price: $19.09 info
Change: +$5.39 (+39%) info
Market Cap: $1.808B info
REPL
Aug 11, 2026, 5:46 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $13.66
Real-time Price: $19.09 info
Change: +$5.43 (+40%) info
Market Cap: $1.808B info
REPL
Aug 10, 2026, 6:37 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $13.65
Real-time Price: $19.09 info
Change: +$5.44 (+40%) info
Market Cap: $1.808B info
REPL
Aug 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.63
Real-time Price: $19.09 info
Change: +$6.46 (+51%) info
Market Cap: $1.808B info
REPL
Aug 10, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.69
Real-time Price: $19.09 info
Change: +$7.40 (+63%) info
Market Cap: $1.808B info
REPL
Aug 10, 2026, 7:39 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $12.93
Real-time Price: $19.09 info
Change: +$6.16 (+48%) info
Market Cap: $1.808B info
REPL
Aug 07, 2026, 7:49 AM EDT
Source: Benzinga
Importance Score:
10
Price at Filing: $12.50
Real-time Price: $19.09 info
Change: +$6.59 (+53%) info
Market Cap: $1.808B info
REPL
Aug 06, 2026, 9:27 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $12.97
Real-time Price: $19.09 info
Change: +$6.12 (+47%) info
Market Cap: $1.808B info
REPL
Jul 30, 2026, 5:27 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $5.41
Real-time Price: $19.09 info
Change: +$13.68 (+253%) info
Market Cap: $1.808B info
REPL
Jul 30, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $19.09 info
Change: +$13.59 (+247%) info
Market Cap: $1.808B info
REPL
Jul 28, 2026, 7:45 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $6.81
Real-time Price: $19.09 info
Change: +$12.28 (+180%) info
Market Cap: $1.808B info
REPL
Jul 24, 2026, 4:57 PM EDT
Filing Type: S-3/A
Importance Score:
8
Price at Filing: $9.71
Real-time Price: $19.09 info
Change: +$9.38 (+97%) info
Market Cap: $1.808B info
REPL
Jul 13, 2026, 5:20 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $9.94
Real-time Price: $19.09 info
Change: +$9.16 (+92%) info
Market Cap: $1.808B info
REPL
Jun 29, 2026, 8:12 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $11.40
Real-time Price: $19.09 info
Change: +$7.69 (+67%) info
Market Cap: $1.808B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets